TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01461733
Drug: amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard dose amiodarone
Study: NCT02939209
Drug: Hydromorphone Hcl 2Mg Tab
Normalized name: HYDROMORPHONE HCL 2MG TAB
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given 2 mg hydromorphone (immediate release formulation) in the post anesthetic care unit.
Study: NCT02240459
Drug: fesoterodine 4mg
Normalized name: fesoterodine fumarate 4 MG
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
Study: NCT02240459
Drug: Oxybutynin
Normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
Study: NCT02240459
Drug: fesoterodine 8mg
Normalized name: fesoterodine fumarate 8 MG
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2, 4mg fesoterodine capsules taken together in the morning
Study: NCT00803712
Drug: Cinacalcet
Normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.
Study: NCT00803712
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.
Study: NCT05178823
Drug: Chlorhexidine mouthwash
Normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of oral rinses
Study: NCT04380376
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalations with low doses of Melphalan for 7-10 consequent days
Study: NCT02876796
Drug: GS-0976
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule(s) administered orally
Study: NCT04052607
Drug: LH Suppression
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation protocols
Study: NCT02360774
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
Study: NCT01757197
Drug: Toclizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg IV, once every 1-2 weeks. The maximum dose per infusion should not exceed 800 mg.
Study: NCT01082679
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily for 12 months
Study: NCT01082679
Drug: buprenorphine (Suboxone)
Normalized name: buprenorphine / naloxone Sublingual Film [Suboxone]
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: daily for 12 months
Study: NCT02415192
Drug: Levacalm
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02415192
Drug: Valsartan/amlodipine
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03161041
Drug: bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
Study: NCT01194375
Drug: High Strength IDP-107
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day for 16 weeks
Study: NCT00762762
Drug: Triclosan/copolymer/fluoride
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush whole mouth 2x/day for 12 months with triclosan/copolymer/fluoride toothpaste. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
Study: NCT00762762
Drug: Fluoride
Normalized name: Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Swished around whole mouth twice daily for 12 months. Return for required clinical visits @ 12 months for scaling, root planing and donation samples of dental plaque and blood for microbiological analyses.
Study: NCT00027547
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00027547
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00027547
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00027547
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00678015
Drug: Nordihydroguaiaretic Acid (NDGA)
Normalized name: nordihydroguaiaretic acid, (+/-)-
DrugBank: Masoprocol (DB00179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NDGA 2000mg daily
Study: NCT02408731
Drug: PMZ-2010 (Centhaquin)
Normalized name: Centhaquine
DrugBank: Centhaquine (DB16122)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
Study: NCT00448214
Drug: YM150
Normalized name: Yohimbine
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00448214
Drug: warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT00075452
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00075452
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03981146
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 60 Minute IV Infusion
Study: NCT01239394
Drug: ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly infusion for 8 weeks
Study: NCT01747096
Drug: 68-Ga-DOTANOC
Normalized name: 68-ga-dotanoc
DrugBank: Dotatoc gallium Ga-68 (DB18190)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00630799
Drug: leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 mg i.m.
Study: NCT00334464
Drug: Standard of care or genotyping dosing of warfarin dosing
Normalized name: OIL OF CAMPHOR
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03450759
Drug: AZD9977 ER capsule (fastvrate)
Normalized name: Castor Oil Capsules
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
Study: NCT01223404
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
Study: NCT04321993
Drug: Baricitinib (janus kinase inhibitor)
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner.
Study: NCT04321993
Drug: Remdesivir (antiviral) + barictinib (janus kinase inhibitor)
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).~Baricitinib will be administered as 4 mg po daily for 14 days or until hospital discharge, whichever is sooner.
Study: NCT04321993
Drug: Remdesivir (antiviral)
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remdesivir will be administered as a loading dose of 200 mg IV over one hour on day 1 followed by 100 mg IV daily over one hour on days 2-5 (with a possibility to extend to up to 10 days total).
Study: NCT04321993
Drug: Tocilizumab (interleukin 6 inhibitor)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be administered as a single IV infusion over one hour. Dosage will be 8 mg/kg total bodyweight up to a maximum of 800 mg.
Study: NCT00363688
Drug: Penicillin test and challenge
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01223404
Drug: Mecamylamine
Normalized name: Mecamylamine
DrugBank: Mecamylamine (DB00657)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine
Study: NCT02060370
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose: 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks.
Study: NCT00526448
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/day
Study: NCT00526448
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000-1200 mg/day
Study: NCT00526448
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a 180 mcg/week
Study: NCT00526448
Drug: epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: epoetin beta 450 UI/week
Study: NCT01697800
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00954122
Drug: Quetiapine XR (Seroquel XR)
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral, once daily
Study: NCT00281515
Drug: Lonafarnib
Normalized name: LONAFARNIB
DrugBank: Lonafarnib (DB06448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day
Study: NCT01170975
Drug: Tesetaxel 10 mg with and then without food
DrugBank: Tesetaxel (DB12019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
Study: NCT02467361
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.
Study: NCT02467361
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.
Study: NCT02467361
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.
Study: NCT02049736
Drug: Telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01170975
Drug: Tesetaxel 10 mg without and then with food
DrugBank: Tesetaxel (DB12019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
Study: NCT01511783
Drug: E2609
Normalized name: Elenbecestat
DrugBank: Elenbecestat (DB15391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
Study: NCT00017368
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00017368
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00017368
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00017368
Drug: etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00017368
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00775762
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (75-100 mg)die for three months
Study: NCT00775762
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel (75mg) die for three months
Study: NCT00775762
Drug: clopidogrel plus aspirin
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel 75 mg die plus aspirin 75-100 mg for three months
Study: NCT00017368
Drug: isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00017368
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00017368
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00017368
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03248882
Drug: PF-05221304
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-05221304, Experimental Drug
Study: NCT00833768
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800mg tablets to be taken orally with meals three times per day
Study: NCT00833768
Drug: Placebo for sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo tablets to be taken orally with meals three times per day
Study: NCT02630563
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine will be administered as per center practice.
Study: NCT02630563
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
Study: NCT01439243
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg Tablet
Study: NCT01439243
Drug: Aricept®
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Tablet
Study: NCT04330144
Drug: Hydroxychloroquine as post exposure prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po
Study: NCT03007589
Drug: otc sunscreens
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreens of various SPF levels and ingredients
Study: NCT02855697
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg taken twice daily, equivalent to a total daily dose of 600 mg
Study: NCT02855697
Drug: Cediranib
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg dose of cediranib was selected for this study
Study: NCT02855697
Drug: Platinum-based Chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 2 two courses of platinum-based chemotherapy administered depending on trial entry point.
Study: NCT01289327
Drug: Sedation with Propofol or Midazolam+Alfentanil for FFB
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sedation was started with intravenous injection of a bolus of 2-4 mg midazolam and 0.5 mg alfentanil or 20-50 mg propofol. It was maintained with intermittent boluses of 1-3 mg intravenous midazolam or 0.5 mg intravenous alfentanil, according to clinical judgment, or with boluses of 10-20 mg intravenous propofol, administered at short intervals (\~2 minutes) or according to clinical judgment.
Study: NCT00416819
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00416819
Drug: etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00416819
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01216878
Drug: losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg tablet
Study: NCT01773083
Drug: unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days
Study: NCT02762448
Drug: Daclatasvir+ Asunaprevir
Normalized name: asunaprevir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HCV clearance and complete regression of NHL by ASV+ DCV
Study: NCT01828970
Drug: Basal-bolus detemir-aspart insulin regimen
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After the first CGM was completed during the conventional anti-diabetic treatment, patients received a rapid-acting insulin analogue before each meal (i.e., aspart) and a basal long-acting insulin analogue (i.e., detemir) once or twice daily. The analogues were titrated for optimal glycemic control. After one month of the aspart and detemir regimen, a physician adapted the insulin doses according to the glucose values observed from the second CGM.
Study: NCT01419470
Drug: dapoxetine
Normalized name: dapoxetine
DrugBank: Dapoxetine (DB04884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. multiple dosing~2. 12 subjects will be administered YHD1044 (I, III, V) or active/placebo comparators;dapoxetine
Study: NCT00504608
Drug: Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
DrugBank: Emfilermin (DB06562)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04680195
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients were treated with thalidomide tanken orally every night for 4 months, and the treatment period was divided into induction period and maintenance period, as follows:~Induction period:~The oral dose of thalidomide started at 50 mg, and increased to 100 mg after one week if tolerable, and maintain 100 mg for three weeks. The medication time was 1 month.~Maintenance period: The oral dose of thalidomide was 50-75mg/d. The medication time was 3 months.
Study: NCT04076943
Drug: Roxadustat
Normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Roxadustat will be administered per schedule specified in the arm description.
Study: NCT00941967
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00941967
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00941967
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally.
Study: NCT03414333
Drug: GLP-1
Normalized name: rGLP-1
DrugBank: rGLP-1 (DB05433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 is an hormone secreted by gut in response to nutrients ingestion.
Study: NCT00700375
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
Study: NCT00700375
Drug: Sodium Chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
Study: NCT03477292
Drug: Duration of antibiotic
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duration of antibiotic for treatment of VAP
Study: NCT02244047
Drug: Bifidobacterium breve
Normalized name: Bifidobacterium Breve
DrugBank: Bifidobacterium breve (DB16549)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00789620
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 mg/kg as Bolus intraoperative: 2 mg/kg/h postoperative: 1.3mg/kg/h during 24h
Study: NCT00209391
Drug: Gadodiamide Injection
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02169505
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose increased to 1.8 mg/kg by vein after the second cycle for all subsequent cycles.
Study: NCT00874315
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.8 mg/kg/dose for total of 8 doses.
Study: NCT00874315
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg/dose every 12 hours.